We are proud to announce the publication of the results at 1-Year of the HighLife TSMVR Feasibility Study in the Journal of the American College of Cardiology (#JACC) : Cardiovascular Interventions!
The outcomes of the 30 first patients were assessed during 1 year of follow-up, they demonstrate a high technical success rate, excellent valve function, no left ventricular outflow tract obstruction, and no need for mitral valve reintervention.
Learn more about the publication on this link : 1-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: The HighLife TSMVR Feasibility Study | JACC: Cardiovascular Interventions
“In summary, the HighLife Transfemoral Transseptal Transcatheter Mitral Valve Replacement system appears to be a promising device in the TMVR arsenal, offering a reasonably safe alternative to the transapical approach, with effective and durable MR reduction, as well as a substantial improvement in quality of life at 1-year follow-up”. Dr Nicole Karam
Discover also the editorial comment about this study published in the same edition by Dr Nicole Karam : HighLife Transfemoral Mitral Replacement System: Promises and Uncertainties∗ | JACC: Cardiovascular Interventions